Immunitybio Inc (IBRX)
NASDAQ:IBRX
Want to see IBRX full AI Analyst Report?
IBRX Stock Chart & Stats
$7.70
-$0.11(-4.03%)
At close: 4:00 PM EST
$7.70
-$0.11(-4.03%)
Day’s Range― - ―
52-Week Range$1.95 - $12.43
Previous CloseN/A
Volume1.20M
Average Volume (3M)14.07M
Market Cap
$7.57B
Enterprise Value$8.80B
Total Cash (Recent Filing)$380.88M
Total Debt (Recent Filing)$1.12B
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Aug 12, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding1,047,354,000
10 Day Avg. Volume17,752,741
30 Day Avg. Volume14,072,387
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)-3.65
Price to Sales (P/S)16.08
P/FCF Ratio-5.90
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue62.39
Enterprise Value/Gross Profit66.52
Enterprise Value/Ebitda-45.87
Forecast
1Y Price Target
$13.00Price Target Upside68.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$218.28M
Bulls Say, Bears Say
Bulls Say
Transformational ANKTIVA Revenue GrowthA 700% YoY revenue jump to $113M and accelerating quarterly sales demonstrate durable commercial adoption in the U.S. High volumes and reported repeat prescribing indicate a scalable product franchise that can convert into predictable recurring revenue and support continued investment in label expansion and commercialization.
Issued U.S. Patents Protecting Anktiva+BCGA multi-patent portfolio through 2035 on the Anktiva+BCG combination creates a meaningful exclusivity moat. This intellectual property support reduces competitive entry risk, underpins pricing and contracting leverage, and protects the core commercial franchise and supplemental BLA ambitions over the medium term.
Exclusive Tokyo-172 BCG U.S. Supply AgreementA 10-year exclusive U.S. supply/development deal materially improves BCG supply resilience amid chronic shortages. Securing an additional BCG source supports sustained ANKTIVA+BCG administration, lowers delivery risk for urologists, and strengthens commercialization scalability and market access prospects.
Bears Say
Negative Stockholders' EquityA deeply negative equity position reflects cumulative losses and weak capital buffers. Structurally this limits financial flexibility, increases reliance on external financing or related-party support, and heightens vulnerability to adverse trial, regulatory, or commercial setbacks that could impair long-term execution.
Persistent Cash BurnSustained negative operating and free cash flow at scale means the business requires continuous financing to fund commercial expansion and R&D. This structural cash burn increases dilution or financing costs over time and constrains optionality for opportunistic investment or slower-than-expected launches.
Regulatory And Promotional Compliance RiskPrior 'refuse to file' actions and a Warning Letter on promotional materials highlight persistent regulatory and compliance risks. These can delay label expansions, complicate reimbursement timing, and require ongoing investment in controls and data generation, slowing structural uptake outside the U.S.
ImmunityBio News
IBRX FAQ
What was Immunitybio Inc’s price range in the past 12 months?
Immunitybio Inc lowest stock price was $1.95 and its highest was $12.43 in the past 12 months.
What is Immunitybio Inc’s market cap?
Immunitybio Inc’s market cap is $7.57B.
When is Immunitybio Inc’s upcoming earnings report date?
Immunitybio Inc’s upcoming earnings report date is Aug 12, 2026 which is in 70 days.
How were Immunitybio Inc’s earnings last quarter?
Immunitybio Inc released its earnings results on May 07, 2026. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.07 by -$0.55.
Is Immunitybio Inc overvalued?
According to Wall Street analysts Immunitybio Inc’s price is currently Undervalued.
Does Immunitybio Inc pay dividends?
Immunitybio Inc does not currently pay dividends.
What is Immunitybio Inc’s EPS estimate?
Immunitybio Inc’s EPS estimate is -0.08.
How many shares outstanding does Immunitybio Inc have?
Immunitybio Inc has 1,047,354,000 shares outstanding.
What happened to Immunitybio Inc’s price movement after its last earnings report?
Immunitybio Inc reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.07. Following the earnings report the stock price went down -7.399%.
Which hedge fund is a major shareholder of Immunitybio Inc?
Currently, no hedge funds are holding shares in IBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImmunityBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (68.83% Upside)
$13.00 (68.83% Upside)
Blogger Sentiment
Bullish
IBRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 133.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
170.78%
12-Months-Change
Fundamentals
Return on Equity
138.69%
Trailing 12-Months
Asset Growth
112.88%
Trailing 12-Months
Company Description
Immunitybio Inc
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
IBRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong commercial traction for ANKTIVA with very large year-over-year revenue and unit growth, multiple regulatory milestones (including EU conditional authorization and Saudi first-in-world lung cancer approval), robust enrollment and promising clinical signals across randomized and single-arm QUILT programs, and strategic commercial partnerships and manufacturing initiatives. Offsetting these positives are substantial operating losses and cash burn, significant balance sheet liabilities, continued high R&D investment (including a one-time $14M equipment write-off), and some regulatory delays and market-access complexity in certain cohorts and geographies. Overall, the company is demonstrating clear commercial momentum and clinical progress but remains capital-intensive and faces execution and regulatory risks as it scales internationally.View all IBRX earnings summariesIBRX Stock 12 Month Forecast
Average Price Target
$13.00
▲(68.83% Upside)
Technical Analysis
Catalyst Pharma
―
Immunovant
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Ownership Overview
62.91% Insiders
3.96% Mutual Funds
2.62% Other Institutional Investors
24.24% Public Companies and Individual Investors